Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: Ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab

Journal of Cutaneous Medicine and Surgery

Volumn 18, Issue 3, 2014, Pages 156-169

  Tausend, William ^a   Downing, Christopher ^a   Tyring, Stephen ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BRIAKINUMAB; BRODALUMAB; CYCLOSPORIN; ETANERCEPT; ETRETIN; GUSELKUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; METHOTREXATE; MK 322; PLACEBO; SCH 900222; SECUKINUMAB; TILDRAKIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB; MONOCLONAL ANTIBODY;

ACUTE HEART INFARCTION; ANKYLOSING SPONDYLITIS; ASTHMA; BRAIN INFARCTION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; IMMUNOPATHOGENESIS; INFECTION; INJECTION SITE ERYTHEMA; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PRIORITY JOURNAL; PRODUCTIVITY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCORING SYSTEM; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN CANCER; STATIC PHYSICIAN GLOBAL ASSESSMENT SCORE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VOMITING; WOLFF PARKINSON WHITE SYNDROME; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS; USTEKINUMAB;

EID: 84901029678     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2013.13125     Document Type: Review

References (116)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995;332:581-8, doi:10.1056/NEJM199506293322608.
2. Braun-Falco O, Burg G. Inflammatory infiltrate in psoriasis vulgaris: a cytochemical study. Arch Klin Exp Dermatol 1970;236: 297-314.
3. Nestle FO, Nickoloff BJ. Role of dendritic cells in benign and malignant lymphocytic infiltrates of the skin. Dermatol Clin 1994; 12:271-82. (Pubitemid 24149710)
4. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "type 1"inflammatory gene expression. Trends Immunol 2004;25:295-305, doi:10.1016/j.it.2004.03.006. (Pubitemid 38610353)
5. Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-c, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;1139:752-9, doi:10.1046/j.1523-1747.1999.00749.x.
6. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110-6, doi:10.1001/jama.1986. 03380220076026. (Pubitemid 17045825)
7. Crabtree GR. Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell 1999;96:611-4, doi:10.1016/S0092-8674(00) 80571-1.
8. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-50, doi:10.1056/NEJM200108023450506.
9. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019, doi:10.1111/j.1365-2133.2009.09505.x.
10. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23, doi:10.1067/mjd.2002.120568. (Pubitemid 34073472)
11. Astellas. Voluntary US market discontinuation of Amevive# (alefacept). Available at: http://www.amevive.com/Patient%20letter.pdf (accessed July 21, 2013).
12. Berger J, Houff S, Major E. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 2009;1:583-9, doi:10.4161/mabs.1.6.9884.
13. US Food and Drug Administration. Humira: highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2013/125057s310lbl.pdf (accessed July 21, 2013).
14. US Food and Drug Administration. Enbrel: highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2012/103795s5507lbl.pdf (accessed July 21, 2013).
15. US Food and Drug Administration. Remicade: highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2013/103772s5345lbl.pdf (accessed July 21, 2013).
16. Lima X, Abuabara K, Kimball A, et al. Briakinumab. Expert Opin Biol Ther 2009;9:1107-13, doi:10.1517/14712590903092188.
17. Koutruba N, Emer J, Lebwohl M, et al. Review of ustekinumab, an interleukin 12 and interleukin 23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag 2010;6:123-41.
18. Gordon KB, Langlet RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012;132:304-14, doi:10.1038/jid.2011.304.
19. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52 week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84, doi:10.1016/S0140-6736(08)60726-6. (Pubitemid 351671884)
20. Leonardi C, Matheson R, Zacharie C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9, doi:10.1056/NEJMoa1109997.
21. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168:412-21, doi:10. 1111/bjd.12110.
22. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9, doi:10.1056/NEJMoa1109017.
23. US National Institutes of Health. A phase III study in participants with moderate to severe psoriasis (UNCOVER-1). Available at: http://www. clinicaltrials.gov/ct2/show/NCT01474512?term=LY2439821&rank=1 (accessed July 3, 2013).
24. US National Institutes of Health. Efficacy and safety of intravenous and subcutaneous secukinumab in moderate to severe chronic plaque-type psoriasis (STATURE). Available at: http://clinicaltrials.gov/ct2/show/NCT01412944?term= secukinumab&rank51 (accessed July 3, 2013).
25. US National Institutes of Health. Study of efficacy, safety, and withdrawal and retreatment with brodalumab in moderate to severe plaque psoriasis subjects (AMAGINE-1). Available at: http://clinicaltrials.gov/ct2/ show/NCT01708590?term=brodalumab&rank51 (accessed July 3, 2013).
26. Spuls PI, Lecluse LL, Poulsen ML, et al. How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J Invest Dermatol 2010;130: 933-43, doi:10.1038/jid.2009.391.
27. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64:ii65-8, doi:10.1136/ard.2004.031237. (Pubitemid 40288526)
28. Sweeny CM, Tobin AM, Kirby B. Innate immunity in the pathogenesis of psoriasis. Arch Dermatol Res 2011;303:691-705, doi:10.1007/s00403-011-1169-1.
29. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361:496-509, doi:10.1056/NEJMra0804595.
30. Dinarello CA. Proinflammtory cytokines. Chest 2000;118:503-8, doi:10.1378/chest.118.2.503.
31. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51, doi:10.1038/nature05505. (Pubitemid 46232884)
32. Johnson-Huang LM, Lowes MA, Krueger JG. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech 2012;5:423-33, doi:10.1242/dmm.009092.
33. Lyakh L, Trinchieri G, Provezza L, et al. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 2008;226:112-31, doi:10.1111/j.1600-065X.2008.00700.x.
34. Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1996;1:88-97. (Pubitemid 126669376)
35. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059-68, doi:10.1016/j.jaad.2007. 07.016.
36. Yeilding N, Szapary P, Brodmerkel C, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci 2011;1222:30-9, doi:10.1111/j.1749-6632.2011.05963.x.
37. Wiekowski MT, Leach MW, Evans EW, et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol 2001;166:7563-70. (Pubitemid 32525637)
38. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-603, doi:10.1084/jem.183.6.2593. (Pubitemid 26193037)
39. Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007;9:461-7, doi:10.1007/s11926-007-0075-1. (Pubitemid 350305203)
40. Leipe J, Grunke M, Dechant C, et al. Th17 cells in autoimmune arthritis. Arthritis Rheum 2010;62:2876-85, doi:10.1002/art.27622.
41. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11, doi:10.1038/sj.jid.5701213. (Pubitemid 351543220)
42. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30, doi:10.1084/jem.20030451.
43. Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004;202:139-56, doi:10.1111/j.0105-2896.2004.00211.x. (Pubitemid 39576910)
44. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50, doi:10.1016/j.jaad.2008.02.039. (Pubitemid 351509656)
45. Janssen Biotech Incorporated. Highlights of prescribing Information for Stelara®. Available at: http://www.stelarainfo.com/pdf/ PrescribingInformation.pdf#zoom=100 (accessed July 3, 2013).
46. Cingoz O. Ustekinumab. MAbs 2009;1:216-21, doi:10.4161/mabs.1.3.8593.
47. Yeilding N, Szapary P, Brodmerkel C, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci 2011;1222:30-9, doi:10.1111/j.1749-6632.2011.05963.x.
48. Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006;177:4917-26. (Pubitemid 44469828)
49. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92, doi:10.1056/NEJMoa062382. (Pubitemid 46220818)
50. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74, doi:10.1016/S0140-6736(08)60725-4. (Pubitemid 351671883)
51. Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012;166:861-72, doi:10.1111/j.1365-2133.2012.10901.x.
52. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168:844-54, doi:10.1111/bjd.12214.
53. Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013;27:1535-45, doi:10.1111/jdv.12046.
54. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28, doi:10.1056/NEJMoa0810652.
55. Pan F, Brazier NC, Shear NH, et al. Cost utility analysis based on a head-to-head phase III trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. Value Health 2011;14:652-6, doi:10.1016/j.jval.2011.01.006.
56. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011;12:2041-54, doi:10.1517/14656566.2011.590475.
57. Schmitt-Rau K, Rosenbach T, Radtke MA, et al. Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis. Dermatology 2010;221:236-42, doi:10.1159/000320111.
58. Inzinger M, Heshl B, Weger W, et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol 2011;165:640-5, doi:10.1111/j.1365-2133.2011.10396.x.
59. Reich K, Burden AD, Eaton JN, et al. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network metaanalysis of randomized controlled trials. Br J Dermatol 2012;166: 179-88, doi:10.1111/j.1365-2133.2011. 10583.x.
60. Igarashi A, Kuwabara H, Fahrbach K, et al. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. J Dermatolog Treat 2013;24:351-5, doi:10.3109/09546634.2012.697111.
61. US National Institutes of Health. A study of the safety and efficacy of ustekinumab in adolescent patients with psoriasis (CADMUS). Available at: http://clinicaltrials.gov/ct2/show/NCT01090427 (accessed July 3, 2013).
62. US National Institutes of Health. A study of the safety and efficacy of ustekinumab in patients with psoriatic arthritis. Available at: http://clinicaltrials.gov/ct2/show/NCT01009086 (accessed July 5, 2013).
63. US National Institutes of Health. A proof of concept study to evaluate the effectiveness of ustekinumab in hidradenitis suppurativa (HiTS). Available at: http://clinicaltrials.gov/ct2/show/NCT01704534 (accessed July 5, 2013).
64. US National Institutes of Health. A study to evaluate the safety and effectiveness of ustekinumab or golimumab administered subcutaneously (SC) in patients with sarcoidosis. Available at: http://clinicaltrials.gov/ct2/show/ NCT00955279 (accessed July 5, 2013).
65. US National Institutes of Health. Pilot study of ustekinumab for subjects with chronic atopic dermatitis. Available at: http://clinicaltrials.gov/ct2/ show/NCT01806662 (accessed July 5, 2013).
66. US National Institutes of Health. Tacrolimus, sirolimus and ustekinumab vs. tacrolimus and sirolimus for the prevention of acute graft-versus-host disease. Available at: http://clinicaltrials.gov/ct2/show/NCT01713400 (accessed July 5, 2013).
67. US National Institutes of Health. A study to evaluate the safety and efficacy of ustekinumab maintenance therapy in patients with moderately to severely active Crohn's disease (IM-UNITI). Available at: http://clinicaltrials. gov/ct2/show/NCT01369355 (accessed July 5, 2013).
68. US National Institutes of Health. A study of the effectiveness and safety of ustekinumab (STELARA) and CNTO 1959 administered under the skin of patients with active rheumatoid arthritis, despite existing methotrexate therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT01645280 (accessed July 5, 2013).
69. US National Institutes of Health. A study of efficacy and safety of ustekinumab in patients with primary biliary cirrhosis (PBC) who had an inadequate response to ursodeoxycholic acid. Available at: http:// clinicaltrials.gov/ct2/show/NCT01389973 (accessed July 8, 2013).
70. US National Institutes of Health. Ustekinumab for the treatment of patients with active ankylosing spondylitis (TOPAS). Available at: http://clinicaltrials.gov/ct2/show/NCT01330901 (accessed July 8, 2013).
71. US National Institutes of Health. Ustekinumab for active sightthreatening uveitis. Available at: http://clinicaltrials.gov/ct2/show/NCT01647152 (accessed July 8, 2013).
72. US National Institutes of Health. A safety and efficacy study of CNTO1275 in patients with multiple sclerosis. Available at: http://clinicaltrials.gov/ ct2/show/NCT00207727 (accessed July 8, 2013).
73. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis. Arch Dermatol 2008;144:200-7, doi:10.1001/archdermatol.2007.63. (Pubitemid 351287002)
74. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011;12:113-25, doi:10.2165/11538950-000000000-00000.
75. Papp KA, Sundaram M, Bao Y, et al. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol 2013 May 17, doi:10.1111/jdv.12177.
76. Gottlieb AB, Leonardia C, Kerdel F, et al. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165:652-60, doi:10.1111/j.1365- 2133.2011.10418.x.
77. Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165:661-8, doi:10.1111/j.1365-2133. 2011.10419.x.
78. Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011;365:1586-96, doi:10.1056/NEJMoa1010858.
79. US National Institutes of Health. Search results for ABT-875. Available at: http://clinicaltrials.gov/ct2/results?term=ABT-874&Search=Search (accessed July 8, 2013).
80. MedPage Today, LLC and the Perelman School of Medicine at the University of Pennsylvania, Available at: http://www.medpagetoday.com/MeetingCoverage/AAD/ 37664 (accessed July 22, 2013).
81. PeerView Press. Investigational drug provides significant symptom improvement in chronic plaque psoriasis: presented at AAD. Available at: http://www.peerviewpress.com/investigational-drug-provides-significant-symptom- improvement-chronic-plaque-psoriasis-presented-aad (accessed July 22, 2013).
82. US National Institutes of Health. A study to evaluate the efficacy and safety/tolerability of subcutaneous SCH 900222/ Tildrakizumab in participants with moderate-to-severe chronic plaque psoriasis (P07771/Tildrakizumab-011). Available at: http://clinicaltrials.gov/ct2/show/NCT01729754 (accessed July 8, 2013).
83. US National Institutes of Health. A study to evaluate the efficacy and safety of subcutaneous Tildrakizumab, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis (Tildrakizumab-010 AM3). Available at: http://clinicaltrials.gov/ct2/ show/NCT01722331 (accessed July 9, 2013).
84. US National Institutes of Health. Search results for Tildrakizumab. Available at: http://clinicaltrials.gov/ct2/results?term= Tildrakizumab&Search=Search (accessed July 9, 2013).
85. Sofen H, Smith S, Matheson R. Results of a single ascending dose study to assess the safety and tolerability of CNTO 1959 following intravenous or subcutaneous administration in healthy subjects and in subjects with moderate to severe psoriasis. Br J Dermatol 2011;165:e10.
86. Skin & Allergy News. Psoriasis drug pipeline extrudes progress. Available at: http://www.skinandallergynews.com/index.php?id=372&cHash= 071010&tx-ttnews[tt-news]=139625 (accessed July 22, 2013).
87. US National Institutes of Health. A study to evaluate CNTO 1959 in the treatment of patients with moderate to severe plaque-type psoriasis (X-PLORE). Available at: http://clinicaltrials.gov/ct2/show/NCT01483599 (accessed July 9, 2013).
88. US National Institutes of Health. A study of the efficacy, safety and tolerability of CNTO 1959, a human anti-IL 23 monoclonal antibody in participants with palmoplantar pustulosis. Available at: http://clinicaltrials. gov/ct2/show/NCT01845987 (accessed July 9, 2013).
89. US National Institutes of Health. A study to assess the pharmacokinetic comparability of guselkumab (CNTO1959) when delivered by 2 different devices and as 2 formulations in healthy participants. Available at: http://clinicaltrials. gov/ct2/show/NCT01866007 (accessed July 9, 2013).
90. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72, doi:10.1126/scitranslmed.3001107.
91. Rich P, Sigurgiersson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013;168:402-11, doi:10.1111/bjd.12070.
92. US National Institutes of Health. Efficacy and safety of subcutaneous secukinumab for moderate to severe chronic plaque-type psoriasis for up to 1 year (ERASURE). Available at: http://clinicaltrials.gov/ct2/show/NCT01365455 (accessed July 9, 2013).
93. US National Institutes of Health. Efficacy and safety of subcutaneous secukinumab (AIN457) for moderate to severe chronic plaque-type psoriasis assessing different doses and dose regimens (SCULPTURE). Available at: http://clinicaltrials.gov/ct2/show/NCT01406938 (accessed July 9, 2013).
94. US National Institutes of Health. Study of safety, tolerability, and efficacy of secukinumab in subjects with moderate to severe palmoplantar psoriasis (GESTURE). Available at: http://clinicaltrials.gov/ct2/show/ NCT01806597 (accessed July 9, 2013).
95. US National Institutes of Health. Extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab. Available at: http://clinicaltrials.gov/ct2/show/NCT01544595 (accessed July 10, 2013).
96. US National Institutes of Health. Safety and efficacy of secukinumab compared to etanercept in subjects with moderate to severe, chronic plaque-type psoriasis (FIXTURE). Available at: http://clinicaltrials.gov/ct2/show/ NCT01358578 (accessed July 10, 2013).
97. US National Institutes of Health. Extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding secukinumab phase III studies. Available at: http://clinicaltrials.gov/ct2/show/NCT01640951 (accessed July 10, 2013).
98. US National Institutes of Health. First study of secukinumab in pre-filled syringes in subjects with chronic plaque-type psoriasis: response at 12 weeks (FEATURE). Available at: http://clinicaltrials.gov/ct2/show/NCT01555125 (accessed July 10, 2013).
99. US National Institutes of Health. Study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with rheumatoid arthritis. Available at: http://clinicaltrials.gov/ct2/show/NCT01640938 (accessed July 10, 2013).
100. US National Institutes of Health. Efficacy at 24 weeks and long term safety, tolerability and efficacy up to 2 years of secukinumab (AIN457) in patients with active psoriatic arthritis (PsA) (FUTURE 1). Available at: http://clinicaltrials.gov/ct2/show/NCT01392326 (accessed July 11, 2013).
101. US National Institutes of Health. The effects of a single intravenous administration of secukinumab (AIN457) or canakinumab (ACZ885) in dry eye patients. Available at: http://clinicaltrials.gov/ct2/show/NCT01250171 (accessed July 11, 2013).
102. US National Institutes of Health. Efficacy at 16 weeks and long term efficacy, safety and tolerability up to 5 years of secukinumab in patients with active ankylosing spondylitis. Available at: http://clinicaltrials.gov/ct2/show/ NCT01649375 (accessed July 11, 2013).
103. US National Institutes of Health. Safety, tolerability, and efficacy of AIN457 in patients with uncontrolled asthma. Available at: http:// clinicaltrials.gov/ct2/show/NCT01478360 (accessed July 11, 2013).
104. US National Institutes of Health. Efficacy and safety of AIN457 (secukinumab) in patients with relapsing multiple sclerosis. Available at: http://clinicaltrials.gov/ct2/show/NCT01874340 (accessed July 11, 2013).
105. Ren V, Dao H. Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. Clin Cosmet Investig Dermatol 2013;6:75-80.
106. Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012;130:145-54.e9, doi:10.1016/j.jaci.2012. 04.024.
107. US National Institutes of Health. A phase III study in participants with moderate to severe psoriasis (UNCOVER-2). Available at: http://clinicaltrials. gov/ct2/show/NCT01597245 (accessed July 11, 2013).
108. US National Institutes of Health. A study in participants with moderate to severe psoriasis (UNCOVER-3). Available at: http://clinicaltrials.gov/ct2/ show/NCT01646177 (accessed July 11, 2013).
109. US National Institutes of Health. A study of ixekizumab in participants with active psoriatic arthritis (SPIRIT-P1). Available at: http:// clinicaltrials.gov/ct2/show/NCT01695239 (accessed July 11, 2013).
110. US National Institutes of Health. Study of ixekizumab in participants with active ankylosing spondylitis (AS) (SPIRIT A1). Available at: http://clinicaltrials.gov/ct2/show/NCT01870284 (accessed July 12, 2013).
111. Papp KA, Reid C, Foley P, et al. Blockade of the IL-17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in psoriatic skin, including substantial pathway specific effects within one week. J Invest Dermatol 2012;132:2466-9, doi:10.1038/jid.2012.163.
112. US National Institutes of Health. Study of efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis subjects (AMAGINE-2). Available at: http://clinicaltrials.gov/ct2/ show/NCT01708603 (accessed July 12, 2013).
113. US National Institutes of Health. Study of efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis subjects (AMAGINE-3). Available at: http://clinicaltrials.gov/ct2/ show/NCT01708629 (accessed July 12, 2013).
114. US National Institutes of Health. Safety and efficacy of AMG 827 in subjects with RA. Available at: http://clinicaltrials.gov/ct2/show/NCT01059448 (accessed July 12, 2013).
115. US National Institutes of Health. A study to evaluate the dosing of AMG 827 for subjects with inadequately controlled asthma. Available at: http://clinicaltrials.gov/ct2/show/NCT01199289 (accessed July 12, 2013).
116. US National Institutes of Health. AMG 827 in subjects with psoriatic arthritis. Available at: http://clinicaltrials.gov/ct2/show/NCT01516957 (accessed July 12, 2013).